![](/images/graphics-bg.png)
Overcoming Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutated Tumours
Joint Authors
Paton, Emily L.
Turner, Jacqueline A.
Schlaepfer, Isabel R.
Source
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-14, 14 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-01-03
Country of Publication
Egypt
No. of Pages
14
Main Subjects
Abstract EN
Overactivation of the mitogen-activated protein kinase (MAPK) pathway is an important driver of many human cancers.
First line, FDA-approved therapies targeting MAPK signalling, which include BRAF and MEK inhibitors, have variable success across cancers, and a significant number of patients quickly develop resistance.
In recent years, a number of preclinical studies have reported alternative methods of overcoming resistance, which include promoting apoptosis, modulating autophagy, and targeting mitochondrial metabolism.
This review summarizes mechanisms of resistance to approved MAPK-targeted therapies in BRAF-mutated cancers and discusses novel preclinical approaches to overcoming resistance.
American Psychological Association (APA)
Paton, Emily L.& Turner, Jacqueline A.& Schlaepfer, Isabel R.. 2020. Overcoming Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutated Tumours. Journal of Oncology،Vol. 2020, no. 2020, pp.1-14.
https://search.emarefa.net/detail/BIM-1188836
Modern Language Association (MLA)
Paton, Emily L.…[et al.]. Overcoming Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutated Tumours. Journal of Oncology No. 2020 (2020), pp.1-14.
https://search.emarefa.net/detail/BIM-1188836
American Medical Association (AMA)
Paton, Emily L.& Turner, Jacqueline A.& Schlaepfer, Isabel R.. Overcoming Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutated Tumours. Journal of Oncology. 2020. Vol. 2020, no. 2020, pp.1-14.
https://search.emarefa.net/detail/BIM-1188836
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1188836